P182

Mucormycosis in Northwest Iranian cases with a history of delta COVID-19, a brief report

Kambiz Diba¹, Reza Samarei², Rahim Nejadrahim³, Atefeh Namaki⁴ ¹School of Medicine, Urmia University of Medical Sciences, Urmia, Iran ²Khomeini Training Hospital, Urmia University of Medical sciences, Urmia, Iran ³Taleqani Training Hospital, Urmia, Iran ⁴Arefian General Hospital, Urmia, Iran

Poster session 2, September 22, 2022, 12:30 PM - 1:30 PM

Objectives: *Mucoral* fungi are the opportunistic organisms causing invasive or localized infections in persons with conditions such as diabetes mellitus, immune suppression, and corticosteroid therapy. During the recent surge of delta-type Coronavirus disease 2019 (COVID-19) in Iran, the rate of invasive mucormycosis considerably increased as a cluster in society. COVID-19-ascoited mucormycosis (CAM) immerged as a severe and life-threatening infection. The present report includes demographic, clinical and laboratory diagnostic information about newly emerged CAM in Northwest of Iran.

Methods: During three months, from August to October 2021, about 65 cases with clinical manifests suspected of mucormycosis and a history of recent severe COVID-19 and corticosteroid therapy with dexamethasone were studied. Clinical specimens obtained from sinuses and upper respiratory tract, transported to Clinical Mycology Center, UMS University, Urmia, Iran for the detection of and molecular identifications of *mucoral* and other agents. Our subjects were the clinical specimens including 31 nasal biopsies, 24 paranasal sinus biopsies, 2 facial and palate biopsies, skin and sutures, one each. Also, two samples of bronco-alveolar lavage were used for investigating fungi in the respiratory tract.

Results: More than 52% of the patients were men and the most frequent age range was 50-60 years. Most frequent clinical specimens were sent from ENT wards and ICUs, 22 (33.8%) and 12 (18.5%) respectively. Among all confirmed cases of CAM, 18 (27.7%) suffred from a background of diabetes but 46 (70.8%) had no underlying diseases. Our findings of direct examination showed 55 (84.6%) *mucoral* elements. The suspected cases of CAM showed clinical manifests including acute sinusitis, thino-sino-cerebral 25 (38.5%), thino-sino-orbital 7 (10.8%), and sino-facial 3 (4.6%), involvements. The culture and identification resulted in *Khizopus oryzea* as the most frequent isolate (44.6%) and Candida yeasts (albicans and nonalbicans *Candida* species) 6.2%-7.7% respectively. *Aspergillus* species were detected 5 (7.7%) as well. A considerable number of cultures, 20 (30.8%) could result no growth for any fungi.

Conclusion: As a conclusion, delta-type Coronavirus causing a considerable increased invasive Mucormycosis in the recorded COVID-19 cases in the north west of Iran. Although, opportunistic *candida* and *aspergillus* were identified in lower frequencies as well.

Code	Clinical Specimen	Reference	Predisposing Factor	Clinical Manifest	Direct Examination	Culture Identification
2152	Nasal	ICU	None	Sinusitis	Mucoral	R. oryzae
2152	Nasal	ENT	None	Necrosis	Filamentous	A. flavus
2162	BAL	Pulmonology	TB	Infiltration	Yeast	C. albicans
2163	Sinus	Nephrology	Kidney Graft	Sinusitis	Mucoral	R. oryzae
2166	Nasal	Nephrology	Diabetes Mellitus	RSCerebral*	Mucoral	R. oryzae
2167	Nasal	Neurology	None	RSCerebral	Mucoral	R. oryzae
2172	Nasal	Neurology	None	RSCerebral	Mucoral-Yst	C. albicans
2175	Nasal	Neurology	None	RSCerebral	Mucoral	R. oryzae
2176	Nasal	ENT	Diabetes Mellitus	RSOrbital**	Mucoral	R. oryzae
2177	Nasal	Neurology	None	RSCerebral	Mucoral	R. oryzae
2178	Nasal	Pulmonology	None	RSOrbital	Mucoral	R. oryzae
2183	Nasal	Pulmonology	None	RSCerebral	Mucoral-Yst	Non alb Candida
2184	Nasal	Neurosurgery	None	RSCerebral	Mucoral	R. oryzae
2185	Nasal	Neurosurgery	None	RSCerebral	Mucoral	R. oryzae
2189	Nasal	ENT	None	Sinusitis	Mucoral	R. oryzae
2193	Nasal	ENT	None	Sinusitis	Mucoral	R. oryzae
2198	Nasal	Neurosurgery	None	RSCerebral	Mucoral	R. oryzae
2203	Nasal	ENT	None	Sinusitis	Mucoral	R. oryzae
2209	Nasal	ENT	None	Sinusitis	Filamentous	A. flavus
2213	Palate	Surgery	None	NOral	Yeast	Non alb Candida
2215	Sinus	ENT	None	Sinusitis	Mucoral	R. oryzae
2228	Sinus	Neurosurgery	None	RSCerebral	Mucoral	R. oryzae
2229	Facial	ENT	Diabetes Mellitus	SFacial	Mucoral	R. oryzae
2242	Sinus	ICU	None	Sinusitis	Mucoral	R. oryzae
2243	BAL	Pulmonology	None	Dyspnea	Yeast	C. albicans
2244	Sinus	ENT	None	Sinusitis	Mucoral	R. oryzae
2247	Sinus	Neurosurgery	Diabetes Mellitus	RSCerebral	Mucoral	R. oryzae
2251	Sinus	ICU	None	Sinusitis	Mucoral	R. oryzae
2253	Sinus	ENT	Diabetes	Sino-Orbit	Mucoral	R. oryzae
2264	Nasal	Pulmonology	None	Sinusitis	Mucoral	R. oryzae
2266	Sputum	ICU	None	Dyspnea	Yeast	C. albicans
2267	Sinus	Pulmonology	None	Sinusitis	Filamentous	A. flavus
2274	Nasal	Neurosurgery	None	Sinusitis	Mucoral	A. niger
2277	Nasal	ICU	Diabetes Mellitus	Sinusitis	Mucoral	R. oryzae
2283	Sinus	ENT	None	Sinusitis	Mucoral	Non alb Candida
2292	Sinusitis	Neurosurgery	None	SFacial	Mucoral	R. oryzae
2294	Sinus	ENT	None	Sinusitis	Yeast	Non alb Candida
2304	Nasal	Neurosurgery	None	RFacial***	Mucoral	R. oryzae
2306	Sinus	ICU	None	Sinusitis	Yeast	Non alb Cand
2319	Nasal	ENT	None	Sinusitis	Mucoral	R. oryzae
2320	Sinus	ENT	None	Sinusitis	Mucoral	Nogroth
2322	Skin	Infectious	None	Ulcer	Mucoral	R. oryzae